Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 2
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Phase I, Open-Label, Single-Center, Frequency-Escalation Study of the Safety, Tolerability, and Preliminary Efficacy of Neural Stem Cell-Derived Exosomes in Patients With Moderate-to-Severe Early-Onset Alzheimer's Disease
Alzheimer Disease (AD)
Enrolment: 9 · Results not recorded
Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke: an Exploratory Clinical Trial
Ischemic Stroke, Acute
Enrolment: 38 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseSpinal cord injuryUnspecifiedC57BL/6Female
Model: Acute traumatic spinal cord injury in mice
Neural stem cell-derived exosomes increased microvascular density, reduced spinal cord cavity size and improved Basso mouse scale scores, with effects partially abolished by VEGF-A knockdown.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.